ZFIN Image: Norden et al., 2009, Fig. 7

Image

Figure Caption

Fig. 7 IKNM Movements Are Inhibited when MyosinII Activity Is Blocked, but the Effect Can be Rescued by MRLC2^T18DS19D

(A) Images from Movies S13–S15 at 3 hr intervals. Pseudocolored nuclei in WT (upper panel) travel further than nuclei treated with 100 μM Blebbistatin or 25 mM BDM (lower panels). Arrows mark a mitotic but not separated nucleus in BDM treatment.

(B) Stochastic motion velocity distributions for Blebbistatin- and BDM-treated embryos, and centrin morphants and DNp150-expressing cells treated with BDM.

(C) Stochastic motion MSD profiles (error bars show 95% confidence intervals) with linear fit for Blebbistatin- and BDM-treated embryos, and centrin morphant and DNp150-expressing cells treated with BDM.

(D) Stochastic motion velocity distributions for BDM-treated embryos injected with MRLC2^T18DS19D-GFP or wild-type MRLC2-GFP, respectively.

(E) Stochastic motion MSD profiles (error bars show 95% confidence intervals) with linear fit for BDM-treated embryos injected with MRLC2^T18DS19D-GFP or MRLC2-GFP, respectively. Only the activated MRLC partially rescues the effect of BDM treatment.

Scale bars represent 10 μm.

Figure Data

Phenotype details

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image.

Reprinted from Cell, 138(6), Norden, C., Young, S., Link, B.A., and Harris, W.A., Actomyosin is the main driver of interkinetic nuclear migration in the retina, 1195-1208, Copyright (2009) with permission from Elsevier. Full text @ Cell